Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Debbie Robbrecht

Showing results (11-20 of 15) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 15 results.
Clinical and Translational Science|June 20, 2024
Safety, pharmacokinetics, pharmacodynamics, and antitumor activity of SAR439459, a TGFβ inhibitor, as monotherapy and in combination with cemiplimab in patients with advanced solid tumors: Findings from a phase 1/1b studyJoaquina C Baranda, Debbie Robbrecht, Ryan Sullivan, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 3, 2021
Systemic Blockade of Clever-1 Elicits Lymphocyte Activation Alongside Checkpoint Molecule Downregulation in Patients with Solid Tumors: Results from a Phase I/II Clinical TrialReetta Virtakoivu, Jenna H Rannikko, Miro Viitala, et al.
Cell Reports. Medicine|December 6, 2023
Bexmarilimab-induced macrophage activation leads to treatment benefit in solid tumors: The phase I/II first-in-human MATINS trialJenna H Rannikko, Loic Verlingue, Maria de Miguel, et al.
Clinical and Translational Science|February 16, 2024
Biomarker and pharmacodynamic activity of the transforming growth factor-beta (TGFβ) inhibitor SAR439459 as monotherapy and in combination with cemiplimab in a phase I clinical study in patients with advanced solid tumorsDebbie Robbrecht, Jean-Jacques Grob, Oliver Bechter, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 1, 2025
Pasritamig, a First-in-Class, Bispecific T-Cell Engager Targeting Human Kallikrein 2, in Metastatic Castration-Resistant Prostate Cancer: A Phase I StudyMark N Stein, Armelle Vinceneux, Debbie Robbrecht, et al.
Pageof 2

Showing results (11-20 of 15) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 15 results.
Clinical and Translational Science|June 20, 2024
Safety, pharmacokinetics, pharmacodynamics, and antitumor activity of SAR439459, a TGFβ inhibitor, as monotherapy and in combination with cemiplimab in patients with advanced solid tumors: Findings from a phase 1/1b studyJoaquina C Baranda, Debbie Robbrecht, Ryan Sullivan, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 3, 2021
Systemic Blockade of Clever-1 Elicits Lymphocyte Activation Alongside Checkpoint Molecule Downregulation in Patients with Solid Tumors: Results from a Phase I/II Clinical TrialReetta Virtakoivu, Jenna H Rannikko, Miro Viitala, et al.
Cell Reports. Medicine|December 6, 2023
Bexmarilimab-induced macrophage activation leads to treatment benefit in solid tumors: The phase I/II first-in-human MATINS trialJenna H Rannikko, Loic Verlingue, Maria de Miguel, et al.
Clinical and Translational Science|February 16, 2024
Biomarker and pharmacodynamic activity of the transforming growth factor-beta (TGFβ) inhibitor SAR439459 as monotherapy and in combination with cemiplimab in a phase I clinical study in patients with advanced solid tumorsDebbie Robbrecht, Jean-Jacques Grob, Oliver Bechter, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 1, 2025
Pasritamig, a First-in-Class, Bispecific T-Cell Engager Targeting Human Kallikrein 2, in Metastatic Castration-Resistant Prostate Cancer: A Phase I StudyMark N Stein, Armelle Vinceneux, Debbie Robbrecht, et al.
Pageof 2